Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial

Año publicación: 2024

Subir documento: https://drive.google.com/file/d/1BtzOOTjySSyL2kYF39TizS3fImDHjZNt/view?usp=sharing

Nombre investigadores: Jesús Argente, Charles F Verge, Uzoma Okorie, Ilene Fennoy, Megan M Kelsey, Casey Cokkinias, Cecilia Scimia, Hak-Myung Lee, I Sadaf Farooqi